Article citationsMore>>

Holmes, C., Ballard, C., Lehman, D., David Smith, A., Beaumont, H., Day, I.N., Nadeem Khan, M., Lovestone, S., McCulley, M., Morris, C.M., Munoz, D.G., O’Brien, K., Russ, C., Del Ser, T. and Warden, D. (2005) Rate of Progression of Cognitive Decline in Alzheimer’s Disease: Effect of Butyrylcholinesterase K Gene Variation. Journal of Neurology, Neurosurgery & Psychiatry, 76, 640-643. http://dx.doi.org/10.1136/jnnp.2004.039321

has been cited by the following article:

• TITLE: Prevalence of Wild-Type Butyrylcholinesterase Genotype in Patients with Alzheimer’s Dementia

  AUTHORS: Beate Mueller, Georg Adler

  KEYWORDS: Butyrylcholinesterase, Alzheimer’s Disease, Genotype

  JOURNAL NAME: World Journal of Neuroscience, Vol.5 No.3, June 2, 2015

  ABSTRACT: Approximately, two-thirds patients with Alzheimer’s disease (AD) are reported to have homozygous wild-type butyrylcholinesterase (BuChE) gene expression. It is associated with a higher rate of hydrolysis of acetylcholine, which ultimately leads to increase in the levels of BuChE in advanced stages of the disease. Rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and BuChE, might be of additional benefit in patients with AD with wild-type BuChE allele.